The Risk of Tuberculosis and TNF-alpha Inhibitors
JOURNAL OF PEDIATRIC INFECTION, cilt.11, sa.2, 2017 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 11 Sayı: 2
- Basım Tarihi: 2017
- Doi Numarası: 10.5578/ced.201719
- Dergi Adı: JOURNAL OF PEDIATRIC INFECTION
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- İstanbul Üniversitesi Adresli: Evet
Özet
The clinical use of TNF-alpha inhibitors have been increasing in the treatment of autoimmune disorders. The most common anti-TNF-alpha agents on clinical use are ethanercept, infliximab and adalimumab. TNF-alpha is an important mediator in the pathogenesis of tuberculosis, therefore the use of TNFAI increases the risk of tuberculosis. Patients who are on anti-TNF alpha treatment should be carefully evaluated for tuberculosis risk before and during therapy. The recommended screening tools are detailed history, physical examination, tuberculin skin test and/or interferon gamma (IFN-gamma) release assay and chest X-Ray every six months.